Rhinitis Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | Regeneron, Revolo Biotherapeutics, Anhui Palo Alto, Abdi Ibrahim Pharma, Lyra Therapeutics, Inmunotek, Iltoo Pharma

Rhinitis Pipeline Drugs 2023 (Updated), FDA Approvals, Clinical Trials, MOA, ROA | Regeneron, Revolo Biotherapeutics, Anhui Palo Alto, Abdi Ibrahim Pharma, Lyra Therapeutics, Inmunotek, Iltoo Pharma

(Albany, United States) As per DelveInsight’s assessment, globally, the Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

The Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The Rhinitis pipeline report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, Rhinitis NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Rhinitis Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/rhinitis-pipeline

 

Key Takeaways from the Rhinitis Pipeline Report

  • DelveInsight’s Rhinitis Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline treatment therapies.
  • The leading Rhinitis Companies are working in the market include Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals Inc, Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Sanofi, Hanmi Pharmaceutical Company Limited, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha PHARM.CO Ltd, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Biomay AG, and others.
  • Promisign Rhinitis Pipeline Therapies in the various stages of development include Levocetirizine, BLX-028914, AD17002, Nasapaque Nasal Solution, Mometasone Furoate Nasal Spray, 50 mcg, Beclomethasone Dipropionate (BDP) Nasal Aerosol, MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, and others.
  • On July 2022, Community and Patient Preference Research Pty Ltd has announced drug named Observational in the market. The study seeks to understand patients’ satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).
  • REGN1908-1909 is a novel cocktail of two fully-human monoclonal IgG antibodies, designed to specifically bind and block the Fel d 1 allergen, thus preventing it from binding and triggering the endogenous antibodies that cause allergies (i.e., Immunoglobulin E, or IgE, antibodies). REGN1908-1909 was invented using Regeneron’s proprietary VelocImmune® technology. Currently, it is in phase III stage of clinical trial evaluation to treat Allergic Rhinitis Due to Cat Allergy.
  • IRL201104 was derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It is expected to provide long-term remission for many allergic diseases. IRL201104 has been shown to quickly and markedly reduce lung infiltration of neutrophils in mice following bronchial challenge with lipopolysaccharide stimulating acute neutrophil activation. IRL1104 has a very short circulation exposure following IV administration and acts on neutrophil infiltration quickly but in a transient manner, which may mean that it would be able to provide a marked, but temporary, reduction in lung neutrophilia, potentially allowing the lung some respite from the high level of inflammation. Currently, it is in phase II stage of clinical trial evaluation to treat Seasonal Allergic Rhinitis.

 

Rhinitis Overview

Rhinitis is a condition that typically involves nasal obstruction or congestion, runny nose or post-nasal drip, itchy nose, and/or sneezing. There are various causes for these symptoms, although they are broadly divided into two types: allergic rhinitis (nasal symptoms related to allergy) and non-allergic rhinitis (nasal symptoms that are not related to allergy).

 

For further information, refer to the detailed Rhinitis Unmet Needs, click here for Rhinitis Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/rhinitis-pipeline

 

Rhinitis Emerging Drugs Profile

  • REGN1908-1909: Regeneron
  • IRL201104: Revolo Biotherapeutics

 

Rhinitis Pipeline Therapeutics Assessment

There are approx. 35+ Rhinitis companies which are developing the therapies for Rhinitis. The Rhinitis companies which have their Rhinitis drug candidates in the most advanced stage, i.e. phase III include, Regeneron.

 

Request a sample and discover the recent advances in Rhinitis Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/rhinitis-pipeline

 

Rhinitis Drugs & Companies

  • Levocetirizine: UCB Pharma
  • BLX-028914: Dart NeuroScience LLC
  • Nasapaque Nasal Solution: 3E Therapeutics Corporation
  • Mometasone Furoate Nasal Spray, 50 mcg: Amneal Pharmaceuticals, LLC

 

Rhinitis Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Rhinitis Therapeutics Market include-

Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals Inc, Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Sanofi, Hanmi Pharmaceutical Company Limited, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha PHARM.CO Ltd, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Biomay AG, and others.

 

Dive deep into rich insights for drugs for Rhinitis Pipeline, click here for Rhinitis Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/rhinitis-pipeline

 

Scope of the Rhinitis Pipeline Report

  • Coverage- Global
  • Rhinitis Companies- Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals Inc, Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Sanofi, Hanmi Pharmaceutical Company Limited, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Dong Wha PHARM.CO Ltd, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Biomay AG, and others.
  • Rhinitis Therapies- Levocetirizine, BLX-028914, AD17002, Nasapaque Nasal Solution, Mometasone Furoate Nasal Spray, 50 mcg, Beclomethasone Dipropionate (BDP) Nasal Aerosol, MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, and others.
  • Rhinitis Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Rhinitis Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/rhinitis-pipeline

 

Table of Content

  1. Introduction
  2. Rhinitis Executive Summary
  3. Rhinitis: Overview
  4. Rhinitis Pipeline Therapeutics
  5. Rhinitis Therapeutic Assessment
  6. Rhinitis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. REGN1908-1909: Regeneron
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IRL201104: Revolo Biotherapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Rhinitis Key Companies
  21. Rhinitis Key Products
  22. Rhinitis- Unmet Needs
  23. Rhinitis- Market Drivers and Barriers
  24. Rhinitis- Future Perspectives and Conclusion
  25. Rhinitis Analyst Views
  26. Rhinitis Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services


Posted

in

by

Tags: